

Vetenskapliga publikationer baserade på kvalitetsregistret eller experters kunskaper i NKCx under året 2021

- A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial. *Contemp Clin Trials* 101, 106266.
Baisley, K.J., Whitworth, H.S., Changalucha, J., Pinto, L., Dillner J., Kapiga, S., de Sanjosé, S., Mayaud, P., Hayes, R.J., Lacey, C.J., Watson-Jones, D., 2021.
- Age, margin status, high-risk human papillomavirus and cytology independently predict recurrent high-grade cervical intraepithelial neoplasia up to 6 years after treatment. *Oncol Lett* 22, 684.
Andersson, S., Megyessi, D., Belkić, K., Alder, S., Östensson, E., Mints, M., 2021
- Associations of treated and untreated human papillomavirus infection with preterm delivery and neonatal mortality: A Swedish population-based study. *PLoS Med* 18, e1003641.
Wiik, J., Nilsson, S., Kärrberg, C., Strander, B., Jacobsson, B., Sengpiel, V., 2021.
- Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program
Maria Hortlund, Laila Sara Arroyo Mühr, Camilla Lagheden, Anders Hjerpe, Joakim Dillner
- Colposcopic assessment by Swedescore, evaluation of effectiveness in the Swedish screening programme: a cross-sectional study
Emilia Alfonzo, Erik Holmberg, Ian Milsom, Björn Strander, 11 December 2021
- Cervical screening in high-income countries: the need for quality assurance, adjunct biomarkers and rational adaptation to HPV vaccination. *Prev Med* 144, 106382.
Sundström K., Herweijer E., Wang J., 2021.
- Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries. *J Med Screen* 969141321992404
Partanen V.-M., Dillner J., Tropé A., Ágústsson Á.I., Pankakoski M., Heinävaara S., Sarkeala T., Wang J., Skare G.B., Anttila A., Lönnberg S., 2021.
- Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. *Am J Prev Med* 60, 478–487.
Robles C., Bruni L., Acera A, Riera J.C., Prats L, Poljak M, Mlakar J, Oštrbenk Valenčak A, Eriksson T., Lehtinen M., Louvanto K., Hortlund M., Dillner J., Faber M.T., Munk C, Kjaer S.K., Petry K.U., Denecke A., Xu L., Arbyn M., Cadman L., Cuzick, J., Dalstein V., Clavel C., de Sanjosé S., Bosch F.X., 2021.

- Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs *Am J Epidemiol* 2021 04; 190 (4): 506-514.
Vänskä S, Luostarinen T, Lagheden C, Eklund C, Kleppe S, Andrae B, Sparén P, Sundström K, Lehtinen M, Dillner J
- Distribution of HPV Genotypes Differs Depending on Behavioural Factors among Young Women. *Microorganisms* 9.
Bergqvist L, Kalliala I, Aro K, Auvinen E, Jakobsson M, Kiviharju M, Virtanen S, Dillner J., Nieminen P, Louvanto ., 2021.
- Equal prevalence of severe cervical dysplasia by HPV self-sampling and by midwife-collected samples for primary HPV screening: a randomised controlled trial. *Eur J Cancer Prev* 30, 334–340.
Hellsten C., Ernstson A., Bodelsson, G., Forslund, O., Borgfeld C., 2021.
- Exposure definition in case-control studies of cervical cancer screening: a systematic literature review. *Cancer Epidemiol Biomarkers Prev* cebp.0376.2021.
Castanon, A., Kamineneni, A., Elfstrøm, K.M., Lim, A.W., Sasieni, P., 2021
- International Cancer Screening Network ICSN, 2021. Interruption of cancer screening services due to COVID-19 pandemic: lessons from previous disasters. *Prev Med Rep* 101399.
Puricelli Perin D.M., Christensen T., Burón A., Haas J.S., Kamineneni A., Pashayan N., Rabeneck L., Smith R., Miriam Elfström, Mireille J.M. Broeders, for the International Cancer Screening Network ICSN
- HPV73 in cervical cancer and distribution of HPV73 variants in cervical dysplasia. *Int J Cancer*.
Borgfeldt C., Söderlund-Strand A., Flygh L.D., Forslund O., 2021.
- Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures. *Viruses* 13, 1323.
Arroyo Mühr LS, Guerendiain D, Cuschieri C, Sundström K, 2021.
- Human Papillomavirus Load and Genotype Analysis Improves the Prediction of Invasive Cervical Cancer. *Int J Cancer*.
Hortlund M., van Mol, T., Van de Pol F., Bogers J.-P., Dillner J., 2021.
- Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. *PLOS Med* 18, e1003588.
Gray P., Kann H., Pimenoff V.N., Eriksson T., Luostarinen T., Vänskä S., Surcel H., Faust H., Dillner J., Lehtinen M., 2021.
- Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. *BMJ Open* 11, e050669

Matti Lehtinen, Camilla Lagheden, Tapio Luostarinen, Tiina Eriksson, Dan Apter, Anne Bly, Penelope Gray, Katja Harjula, Kaisa Heikkilä, Mari Hokkanen, Heidi Karttunen, Marjo Kuortti, Pekka Nieminen, Mervi Nummela, J Paavonen, Johanna Palmroth, Tiina Petäjä, Eero Pukkala, Anna Soderlund-Strand, Ulla Veivo, Joakim Dillner

- Nationwide Rereview of Normal Cervical Cytologies before High-Grade Cervical Lesions or before invasive Cervical Cancer. *Acta Cytologica* 2021;65:377–384
Edvardsson H., Wang J., Andrae B., Sparén P., Strander B., Dillner J., 2021 (online ahead of print).
- Non-vaccine HPV genotype common in women with HIV failing cervical precancer treatment. *AIDS*, 2021.
Carlander C., Lagheden C., Eklund C., Kleppe S., Dzabic M., Wagner P., Sparén P., Dillner J.
- Organized primary human papillomavirus–based cervical screening: A randomized healthcare policy trial.
Elfström M., Eklund C., Lamin H., Öhman D., Hortlund M., Elfgrén K., Sundström K., Dillner J. Published: August 23, 2021.
- Promotion of Cervical Screening among Long-term Non-attendees by Human Papillomavirus Self-sampling. *J Cancer Prev* 26, 25–31.
Ernstson A., Forslund O., Borgfeld C., 2021.
- Prospects for accelerated elimination of cervical cancer
Dillner, J., Elfström, K.M., Baussano, I., 2021
- Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources
Wang, W., Kothari, S., Baay, M., Garland, S.M., Giuliano, A.R., Nygård, M., Velicer, C., Tota, J., Sinha, A., Skufca, J., Verstraeten, T., Sundström, K., 2021.
- Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia. *Oncol Lett* 21, 240.
Östensson, E., Belkić, K., Ramqvist, T., Mints, M., Andersson, S., 2021.
- The value of adding a single co-test in HPV primary screening
Jans, L., Zetterström, K., Bergengren, L., Helenius, G., 2021
- The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing. *J Clin Virol* 141, 104902.
Eklund C., Mühr L.S.A., Lagheden C., Forslund O., Dahlin Robertsson K.D., Dillner J., 2021.
- Validation of the cobas 6800 human papillomavirus test in primary cervical screening
Sundström K., Lamin H., Dillner J., 2021.

- 2020 List of human papillomavirus assays Suitable for primary cervical cancer screening. Clin Microbiol Infect.
Arbyn M, Simon M, Peeters E, Meijer C.J.L.M., Berkhof J, Cuschieri K, Bonde J, Oštrbenk Valenčak, A, Zhao F-H, Rezhake R, Gultekin M, Dillner J., de Sanjosé S, Canfell K, Hillemanns P, Almonte M, Xu L, Wentzensen N, Poljak M, 2021. 2020